OBJECTIVE: To evaluate the potential etiologic heterogeneity of breast cancer by examining whether associations with reproductive and other personal characteristics differed by p53 protein expression status. METHODS: Data from the Carolina Breast Cancer Study, a population-based, case-control study of 861 cases and 790 controls, were utilized. Immunohistochemical staining for the p53 protein was performed on 638 archived tumor specimens; 46% of cases were classified as p53+. Two separate unconditional logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals (CI) for p53+ and p53- breast cancer relative to controls for reproductive and other personal characteristics. Analyses were performed separately for younger (< or = 45 years) and older (>45 years) women. RESULTS: Risk factor profiles largely overlapped for p53+ and p53- breast cancer, with the exception of oral contraceptive (OC) use among younger women and a family history of breast cancer. Prolonged OC use was more strongly associated with p53+ breast cancer [OR 3.1 (95% CI: 1.2-8.1) than p53- breast cancer (OR 1.3 (95% CI: 0.6-3.2)] among younger women only. A first-degree family history of breast cancer was associated with p53+ breast cancer among younger women [OR 1.5 (95% CI: 1.0-2.2)] and older women [OR 1.4 (95% CI: 0.9-2.3)], but not p53- breast cancer in either age-group. CONCLUSIONS: These results provide little evidence of breast cancer heterogeneity as classified by p53 expression status. However, although not statistically significant, OC use among younger women and family history of breast cancer may operate through a pathway involving p53 alterations to increase risk of breast cancer.
OBJECTIVE: To evaluate the potential etiologic heterogeneity of breast cancer by examining whether associations with reproductive and other personal characteristics differed by p53 protein expression status. METHODS: Data from the Carolina Breast Cancer Study, a population-based, case-control study of 861 cases and 790 controls, were utilized. Immunohistochemical staining for the p53 protein was performed on 638 archived tumor specimens; 46% of cases were classified as p53+. Two separate unconditional logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals (CI) for p53+ and p53- breast cancer relative to controls for reproductive and other personal characteristics. Analyses were performed separately for younger (< or = 45 years) and older (>45 years) women. RESULTS: Risk factor profiles largely overlapped for p53+ and p53- breast cancer, with the exception of oral contraceptive (OC) use among younger women and a family history of breast cancer. Prolonged OC use was more strongly associated with p53+ breast cancer [OR 3.1 (95% CI: 1.2-8.1) than p53- breast cancer (OR 1.3 (95% CI: 0.6-3.2)] among younger women only. A first-degree family history of breast cancer was associated with p53+ breast cancer among younger women [OR 1.5 (95% CI: 1.0-2.2)] and older women [OR 1.4 (95% CI: 0.9-2.3)], but not p53- breast cancer in either age-group. CONCLUSIONS: These results provide little evidence of breast cancer heterogeneity as classified by p53 expression status. However, although not statistically significant, OC use among younger women and family history of breast cancer may operate through a pathway involving p53 alterations to increase risk of breast cancer.
Authors: Samantha Puvanesarajah; Sarah J Nyante; Cherie M Kuzmiak; Mengjie Chen; Chiu-Kit Tse; Xuezheng Sun; Emma H Allott; Erin L Kirk; Lisa A Carey; Charles M Perou; Andrew F Olshan; Louise M Henderson; Melissa A Troester Journal: Cancer Prev Res (Phila) Date: 2018-04-05
Authors: Colin B Begg; Emily C Zabor; Jonine L Bernstein; Leslie Bernstein; Michael F Press; Venkatraman E Seshan Journal: Stat Med Date: 2013-07-16 Impact factor: 2.373
Authors: Halei C Benefield; Emily C Zabor; Yue Shan; Emma H Allott; Colin B Begg; Melissa A Troester Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-08-08 Impact factor: 4.254
Authors: Amber N Hurson; Mustapha Abubakar; Alina M Hamilton; Kathleen Conway; Katherine A Hoadley; Michael I Love; Andrew F Olshan; Charles M Perou; Montserrat Garcia-Closas; Melissa A Troester Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-11-04 Impact factor: 4.090
Authors: Huiyan Ma; Yaping Wang; Jane Sullivan-Halley; Linda Weiss; Polly A Marchbanks; Robert Spirtas; Giske Ursin; Ronald T Burkman; Michael S Simon; Kathleen E Malone; Brian L Strom; Jill A McDonald; Michael F Press; Leslie Bernstein Journal: Cancer Res Date: 2010-01-12 Impact factor: 12.701
Authors: Kathleen Conway; Eloise Parrish; Sharon N Edmiston; Dawn Tolbert; Chiu-Kit Tse; Patricia Moorman; Beth Newman; Robert C Millikan Journal: Breast Cancer Res Date: 2007 Impact factor: 6.466